AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.59 |
Market Cap | 28.21M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.07 |
PE Ratio (ttm) | -2.46 |
Forward PE | n/a |
Analyst | Strong Buy |
Ask | 2.68 |
Volume | 28,811 |
Avg. Volume (20D) | 56,280 |
Open | 2.58 |
Previous Close | 2.54 |
Day's Range | 2.58 - 2.79 |
52-Week Range | 2.44 - 5.99 |
Beta | undefined |
About MRKR
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill...
Analyst Forecast
According to 1 analyst ratings, the average rating for MRKR stock is "Strong Buy." The 12-month stock price forecast is $19, which is an increase of 621.06% from the latest price.
Next Earnings Release
Analysts project revenue of $1.00M, reflecting a -5.39% YoY shrinking and earnings per share of -0.28, making a -6.67% decrease YoY.